Dear Viewers,
Greetings from " Surgical Educator"
Today in this video I am going to talk on one more cause for Lower GI hemorrhage- Colorectal Carcinoma. I talk on the various causes for Lower GI hemorrhage, Etiopathogenesis, clinical features, investigations, staging, treatment and followup of Colorectal carcinoma. I have also included a mindmap, a diagnostic algorithm and a treatment algorithm. Hope you will enjoy the video. You can watch the video in the following links:
surgicaleducator.blogspot.com
youtube.com/c/surgicaleducator
Thank you for watching the video.
This Presentation gives summarized overview of Gall Bladder Carcinoma especially the management as per latest National Comprehensive Cancer Network(NCCN) Guidelines version 2.2013
Surgical management of pancreatic pseudocyst..by dr chris alumonaCHRIS ALUMONA
Pancreatic pseudocyst is the commonest cystic lesion of the pancreas but generally rare. It commonly complicates pancreatitis and resolves spontaneously with conservative management. Indications for intervention include complications and to rule out malignancy
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Dear Viewers,
Greetings from " Surgical Educator"
Today in this video I am going to talk on one more cause for Lower GI hemorrhage- Colorectal Carcinoma. I talk on the various causes for Lower GI hemorrhage, Etiopathogenesis, clinical features, investigations, staging, treatment and followup of Colorectal carcinoma. I have also included a mindmap, a diagnostic algorithm and a treatment algorithm. Hope you will enjoy the video. You can watch the video in the following links:
surgicaleducator.blogspot.com
youtube.com/c/surgicaleducator
Thank you for watching the video.
This Presentation gives summarized overview of Gall Bladder Carcinoma especially the management as per latest National Comprehensive Cancer Network(NCCN) Guidelines version 2.2013
Surgical management of pancreatic pseudocyst..by dr chris alumonaCHRIS ALUMONA
Pancreatic pseudocyst is the commonest cystic lesion of the pancreas but generally rare. It commonly complicates pancreatitis and resolves spontaneously with conservative management. Indications for intervention include complications and to rule out malignancy
Similar to S11 Approach to Colorectal Carcinoma.pdf (20)
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
5. En. K, 53 years old, Malay gentleman with underlying HPT, dyslipidemia, DM and
obesity presented with altered bowel habit for 4 months
Altered bowel habit
- Previously pass stool once per day with bristol 3-4
- Since 4 months ago, having loose stool (bristol 6), alternating with constipation
- 3-4 episodes per day, amount = 1 small cup (about 200ml)
- Occasionally mix with fresh blood (2-3 episodes per week)
- Half small cup
- No blackish stool/ hematemesis
- No staining over toilet bowl/ tissue/ undergarment
- No anemic symptoms
- No previous blood transfusion
- No mucus in the stool
- Associated with tenesmus
- Occasional feeling of bloatedness
- No fecal incontinence
- No pneumaturia/ fecaluria
6. No abdominal pain
No fever
No history of chronic constipation
No joint pain/ eye pain/ oral ulcers suggestive extra-intestinal sx in IBD
No symptoms of metastasis to liver (RUQ pain/ yellow discoloration of skin)/ lung
(hemoptysis/ SOB)/ bone (back pain)/ brain (headache/ confusion)
No symptoms of intestinal obstruction such as vomitting/ obstipation
No LOA
Has LOW 5kg in 10 months (not significant)
7. Risk factor :
- Consume high amount of red meat - almost daily
- Low fibre diet
- First degree family history of breast cancer (younger sister dx at age of 40)
- Chronic smoker for 20 pack years, starting from 20 years ago started to smoke
1-2 cigarettes only per day
- Obesity class I (BMI 30)
- T2DM
8. Past medical history
Hypertension
- 20 years
- On Amlodipine 10mg OD and Perindopril 4mg OD
- SMBP : 120-125/ 80-90
Dyslipidaemia
- 20 years
- On Simvastatin 40mg OD
T2DM
- 7 years
- On Metformin 1000mg BD & Glicazide 4mg OD
- SMBG: fasting : 7-8 / 2HPP : 9
- No osmotic sx/ no TOD symptoms (chest pain/ unilateral side weakness/ frothy urine/ claudication/
glove-sock numbness/ BOV)
9. Past surgical history
- Nil
Medications and allergies
- Does not consume other
medications/ supplements
- No known drug/ food allergies
Family history
- Father passed away at age of 65 due to
MVA
- Mother currently 75 years old has
underlying HPT/DM/CKD/dyslipidaemia
- 8 siblings (3rd child)
- Others is well and healthy
Social
- Married and blessed with 4 children (all
well and healthy)
- Work as online businessman
- Does not consume alcohol
- Financially stable - medical fees
covered by GL
10. General examination
- Conscious and alert
- Comfortable lying down supine
- Not cachexic looking
Periphery:
- No clubbing
- No stigmata of CLD
- No koilonychia (IDA)
- No bruises/ scratch marks noted over arms
- Pulse rate is 90 bpm, regular rhythm and good volume
- Not pale
- Not jaundice
- Good oral hydration and hygiene
11. Abdominal examination
Inspection
- Abdomen is not distended
- No scars
- No dilated veins/ visible peristalsis
Palpation
- Soft and non tender
- No palpable mass
- No hepatosplenomegaly
- No ballotable kidney
- No shifting dullness
- No inguinal lymphadenopathy
Auscultation
- Bowel sound is present and normal
- No renal/ aortic bruit
Systemic review : unremarkable
15. Investigations
Diagnostic investigation - Colonoscopy
● Direct visualization for the location and size of lesion
● Biopsy for histological investigation
● Detection of synchronous lesions
Staging investigation
● CT-TAP
● MRI Pelvis- rectal cancer
Assessment of complication/fitness for surgery
● FBC
● Liver function test
● CRP
Preoperative investigations
● Carcinoembryogenic antigen (CEA)-tumour marker
● Chest X-ray
● Coagulation Profile
● Renal Profile
● Group Cross Match (GXM)
19. All individuals with family history suggestive of a hereditary colorectal cancer syndrome
should be referred to a clinical genetics service for genetic risk assessment, where accessible.
21. Blood investigations
Hb (13 - 15) g/dL 14
WCC (4 - 10) x 109
/L 7.77
Plt (150 - 410) x 109
/L 393
MCH (27 - 32) pg 27.5
MCV (83 - 101) fl 84.2
Full blood count (pre-op)
Liver function test (pre-op)
Albumin (34 - 48) g/L 36
Total protein (64 - 83) g/L 65
Total bilirubin (3.4 - 20.5)
umol/L
6.8
ALT (0 -55) U/L 13
ALP (40 - 150) U/L 81
Na+
(136 - 145) mmol/L 138
K+
(3.5 - 5.1) mmol/L 4.1
Urea (2.5 - 6.7) mmol/L 2.8
Creatinine
(50.4 - 98.1) umol/L
84
PT (11.7-14.9) seconds 12
INR 0.89
APTT (29.5-43.6) seconds 37.1
(0 - 5) ng/mL 40
Renal Profile
Coagulation profile
CEA
22. Colonoscopy (17/2/22)
1. Retrosigmoid polypoid tumour
2. 15cm-20cm from AV
3. Occupy 50% of the lumen
Impression : rectosigmoid tumour
HPE: Adenocarcinoma, well to moderately
differentiated, arising on a tubulo-villous
adenoma with high grade dysplasia.
CT TAP (8/3/2022)
1. Short segment irregular circumferential bowel wall
thickening seen at rectosigmoid region measuring
approximately 3cm in thickness, 6.2cm in length and
17.5cm from anal verge.
2. Liver is homogeneously enhanced with no focal liver
lesion.
3. No obvious lung nodules
4. Mildly enlarged right paratracheal lymph node with fatty
hilum measuring 1.1cm
24. Surgical management
❖ The mainstay of treatment for colorectal carcinoma is surgical
resection, which offers the best curative outcome.
❖ Chemotherapy and radiotherapy are used to downstage, as adjuvant
therapy and for palliative purposes. The treatments for colon and rectal
carcinoma are outlined in Algorithm C and Algorithm D.
25. Pre operative management
❖ Prophylactic antibiotics (IV Ceftriazone + Metronidazole)
- To cover both aerobes & anaerobes, reduce risk of wound infection &
sepsis
❖ Venous thromboembolism prophylaxis (risk of thromboembolism)
- Anti-embolic stockings (TED stockings)
- Heparin
❖ Bowel preparation
- Should be performed in rectal carcinoma surgery
- May be performed in colon carcinoma surgery
26.
27. Principles of surgery for colonic CA
1. Remove the cancer completely with clear margins
2. Resect adjacent draining lymph nodes
3. Avoid excessive disruption or spillage of tumour cells
4. Reconstruct the bowel, if possible, in order to achieve intestinal continuity and normal or near normal
bowel function post-operatively.
- Main segmental vessels are ligated & divided (i.e. high tie at the IMA for oncological clearance)
- En-bloc resection of tumour with adequate margins. A margin of 5 cm proximally and distally is
adequate. While segmental resection is sufficient for primary tumour removal, a wider resection is
often required to achieve sufficient lymphadenectomy. Adequate clearance of the draining lymphatics
involves excision of the vascular arcades supplying the segment of involved colon back to their origin
(from the SMA or IMA) as lymphatics follow the arteries generally.
28.
29. Right hemicolectomy Tumour site
Caecum/Ascending colon
Structures involved
(excision of structures + division
of blood vessels)
Excision of caecum + ascending
colon
-ileocolic artery
-right colic artery
-right branch of the middle colic
artery
15-20cm + proximal ⅓ transverse
colon
Extended right hemicolectomy Hepatic flexure/transverse
colon near hepatic flexure
Excision of caecum,ascending
colon and proximal transverse
colon
-ileocolic artery
-right colic artery
-middle colic artery(at its origin)
- distal ⅓ transverse colon
30. Left segmental colectomy Transverse colon near splenic
flexure
Excision of distal transverse colon
and proximal descending colon
-left branch of middle colic artery
-left colic artery
Left hemicolectomy Descending colon Excision of descending colon
-left colic artery
-left branch of middle colic artery
-inferior mesenteric vessel
31.
32.
33. Local excision Small tumours
Low anterior resection and Hartmann’s procedure -lesions located in the upper ⅔ of the rectum
-defunctioning stoma decreases clinical anastomotic
leak rate and re-operation rate
Abdominoperineal resection with permanent
colostomy
-rectal tumour sited in the distal ⅓ of the rectum
within 5 cm of anal verge
-involves removal of the anus,rectum and part of the
sigmoid colon with associated regional lymph nodes
34. Stoma
- Artificial opening of a luminal organ into the external environment
- A defunctioning loop ileostomy (or loop colostomy) is usually created during low AR as the manipulation of
the colon deep within the pelvic cavity causes increased risk of an anastomotic leak & also poorer blood
supply to anastomosis (immediate anastomosis is not possible)
- A defunctioning stoma does not protect against anastomotic leak, but mitigates against disastrous
complications of faecal peritonitis should a leak occur
- Closed in 2-6/12 after check with gastrografin reveals no leak (contrast agent during X-ray imaging)
35. Stoma
Ileostomy Colostomy
Location Right iliac fossa Left iliac fossa
Calibre Small Large
Flushed/Spouted Spout- to prevent ileal content
(corrosive) contact to skin
Flushed to the skin
Content Watery greenish ileal output Firm brown faecal output
36. Operative complications
Immediate <24h - Anastomotic leak
- Damage to other organs (ureters,
small bowel, large bowel)
- Bleeding
Early <30d - Wound infection
- Bleeding
- Abscess
- Anastomotic leak -> fecal peritonitis
- Early stoma complications
Late >30d - Diarrhoea
- Impotence
- Adhesions -> IO
- Anastomotic stricture
- Late stoma complications
37. Chemotherapy and radiotherapy
Colon CA
1. Stage 1 & 2
-surgery
2. Stage 2 with high risk features
-adjuvant chemo
3. Stage 3
-fluorouracil (5-FU)/ leucovorin with
oxaliplatin (FOLFOX)
Rectal CA
1. Short course preoperative
radiotherapy is a treatment option
for rectal carcinoma
2. Neoadjuvant chemoradiotherapy
should be offered to T3-T4 / node
positive rectal carcinoma
3. Long course concurrent
chemoradiotherapy may be given
pre or post operatively
38. Follow-up and surveillance
❖ History, physical examination and CEA every 3 to 6 months for 5 years
❖ Surveillance colonoscopy at first year and every 3 to 5 years
❖ CT scan of thorax,abdomen and pelvis is performed annually for 3 years
❖ Encouraged to maintain an ideal body weight,participate in regular physical
activity and consume a well balanced diet